---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000205"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:43:31.499273+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sarepta: $612M FY2021 revenue; SRP-9001 gene therapy shows significant functional improvement in DMD study

## Summary
- Preliminary FY2021 revenue $612M, Q4 revenue $178.7M from DMD therapies; cash $2.1B at year-end.
- SRP-9001 (delandistrogene moxeparvovec): Part 2 of Study 102 met primary endpoint with NSAA improvement vs external control (p=0.0009).
- No new safety signals; no treatment-related SAEs, deaths, or discontinuations in Part 2.
- Company reaffirms confidence in EMBARK phase 3 global study, currently dosing.

## SEC filing metadata
- accession: 0000950170-22-000205
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017022000205/0000950170-22-000205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017022000205/srpt-20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000205
- JSON: https://secwatch.observer/filing/0000950170-22-000205.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.